Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL7197839

N.N.Nc1cccc2c(N)cccc12

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.93
CYP3A4 P08684 5/20 0.93
HPGD P15428 3/20 0.93
TSHR P16473 3/20 0.93
HSD17B10 Q99714 2/20 0.93
TDP1 Q9NUW8 2/20 0.93
NR4A2 P43354 1/20 0.65
KEAP1 Q14145 2/20 0.63
IDO1 P14902 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.52
TTR P02766 1/20 0.52
PARP1 P09874 1/20 0.52
RECQL P46063 1/20 0.52
USP2 O75604 1/20 0.52
TDP2 O95551 1/20 0.52
POLB P06746 1/20 0.52
TDO2 P48775 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27912581 0.96 ALDH1A1 (1.00) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL48843 0.96 ALDH1A1 (1.00) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL29365003 0.96 ALDH1A1 (1.00) ALDH1A1CYP3A4HPGDTSHRHSD17B10
Fluoride SCHEMBL27639109 0.93 ALDH1A1 (0.93) ALDH1A1CYP3A4HPGDTSHRHSD17B10
Hydrochloric Acid SCHEMBL28166221 0.93 CYP3A4 (0.93) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL335367 0.93 ALDH1A1 (0.93) ALDH1A1CYP3A4HPGDTSHRHSD17B10
Hydrochloric Acid SCHEMBL8641121 0.93 CYP3A4 (0.93) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL21854609 0.90 ALDH1A1 (0.87) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL16107418 0.90 ALDH1A1 (0.87) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL14876644 0.90 ALDH1A1 (0.87) ALDH1A1CYP3A4HPGDTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2897933-B1 METHOD OF PRODUCING DIISOCYANATES BY PHOSGENATION OF DIAMINE SUSPENSIONS COVESTRO DEUTSCHLAND AG (DE) 2017-06-07 EP disclosed
US-9272988-B2 Method for producing diisocyanates by phosgenating diamine suspensions COVESTRO DEUTSCHLAND AG (DE) 2016-03-01 US disclosed
US-20150246873-A1 METHOD FOR PRODUCING DIISOCYANATES BY PHOSGENATING DIAMINE SUSPENSIONS BAYER MATERIALSCIENCE AG (DE) 2015-09-03 US disclosed
US-6538158-B2 Process for preparing 1,4-diaminonaphthalene and/or 1,5-diaminoNaphthalene BAYER AKTIENGESELLSCHAFT (DE) 2003-03-25 US disclosed
US-20020198408-A1 Process for preparing 1,4-diaminonaphthalene and/or 1,5-diaminonaphthalene COVESTRO DEUTSCHLAND AG (DE) 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246873-A1 METHOD FOR PRODUCING DIISOCYANATES BY PHOSGENATING DIAMINE SUSPENSIONS DDT, DUS2, SAT1 ALDH1A1 1852/4885CYP3A4 1512/4885HPGD 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.